List view / Grid view
The safety and efficacy of fezolinetant is being evaluated in the Phase III trial of over 1,800 women seeking relief from severe vasomotor symptoms associated with menopause (VMS).
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly.
The report outlines the positive impact the EMA’s PRIority Medicines (PRIME) scheme has had on drug development for unmet medical need over the last five years.
The UK Government has committed £200mn to support NHS-led diagnostics and treatment research and £60 million to expand life sciences manufacturing.
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the Melody Phase III trial.
![Purdue University biomedical engineers have developed new cyber-physical watermarks that allow people to check medication authenticity with a smartphone [Credit: Purdue University photo/John Underwood].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/cyber-physical-watermarks-2-300x278.jpg)
![Purdue University biomedical engineers have developed new cyber-physical watermarks that allow people to check medication authenticity with a smartphone [Credit: Purdue University photo/John Underwood].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/cyber-physical-watermarks-2-scaled-e1646301472554.jpg)
New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.
Pfizer’s investigational C. difficile vaccine was shown to reduce the duration and severity of disease, but not prevent primary C. difficile infection.
New research demonstrates the potential of dual-detection impulsive vibrational spectroscopy (DIVS), an ultrafast Raman spectroscopy technique.
US FDA approval based on 98 percent response rate in multiple myeloma patients treated once with Carvykti (ciltacabtagene autoleucel, cilta-cel).
The EDQM will include Real-Time Remote Inspections (RTEMIS) as an integral part of its system for the supervision of manufacturers of active substances from 2022.
1 March 2022 | By
Serious about Making Pharmaceuticals? Attend the UK’s largest event dedicated to supporting the future of the pharmaceutical product life-cycle.
Brian Henry, Global Head of Drug Product Design at Pfizer, is the new Chair of the Medicines Manufacturing Industry Partnership (MMIP), a body representing the voice of medicines manufacturing in the UK.
USP is developing mRNA quality guidelines to support the development of innovative medicines and vaccines.
New funding for Clinical Research Facilities will boost delivery of first-in-human to early safety and efficacy trials across England.
